Interestingly, CDK9 mRNA levels were significantly higher in castration-resistant neuroendocrine prostate cancer (NEPC) tumors, which exhibit AR-low/null/independent phenotypes, compared to the more common CRPC adenocarcinoma phenotype (Fig. 1c). The gene discussed is CDK9; the disease is adenocarcinoma.